1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Incyte Streamlines Pipeline After Difficult Q1

Company Still Looking For Jakafi Combination

 
• By Andrew McConaghie

The mid-sized pharma company has a blockbuster in Jakafi, but analysts are doubtful about its plans to build on that base across its now slimmed-down pipeline. 

Incyte
• Source: Shutterstock

Incyte is pruning its pipeline with the hope of accelerating the progress of its strongest candidates in hemato-oncology, immunology and dermatology. 

Best known for its blockbuster myelofibrosis treatment Jakafi/Jakavi (ruxolitinib), the mid-sized biopharma company is cutting six discovery programs, one in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.